


Favipiravir

Last Revision: May 11, 2020.

Estimated reading time: 1 minute

CASRN: 259793-96-9



Drug Levels and Effects

Summary of Use during Lactation

Favipiravir is an investigational antiviral drug that is being tested for use against the novel coronavirus disease, COVID-19. No information is available on the use of favipiravir during breastfeeding or its excretion into breastmilk. Favipiravir is a small molecule that is about 60% protein bound in plasma, so it would be expected to appear in breastmilk and be absorbed by the infant, probably in small amounts. In clinical trials, favipiravir has been well tolerated, but has caused liver enzyme abnormalities, gastrointestinal symptoms, and serum uric acid elevations.[1-3] If favipiravir is used in a nursing mother, these parameters should be monitored in the breastfed infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1. Sissoko D, Laouenan C, Folkesson E, et al. Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): A historically controlled, single-arm proof-of-concept trial in Guinea. *PLoS Med.* 2016;13:e1001967 [PMC free article: [PMC4773183](https://pubmed.ncbi.nlm.nih.gov/26930627/)] [PubMed: [26930627](https://pubmed.ncbi.nlm.nih.gov/26930627/)]

2. Scavone C, Brusco S, Bertini M, et al. Current pharmacological treatments for COVID-19: What's next? Br J Pharmacol. 2020 [PubMed: 32329520]
3. Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering (Beijing). 2020 [PMC free article: PMC7185795] [PubMed: 32346491]

Substance Identification

Substance Name

Favipiravir

CAS Registry Number

259793-96-9

Drug Class

Breast Feeding

Lactation

Antiviral Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Copyright Notice

Bookshelf ID: NBK556878 PMID: 32401463